newsfilter
← Latest News
GlobeNewswire·

Eikon Therapeutics Announces Dose Selection for TeLuRide-006, an Ongoing Adaptive Phase 2/3 Trial of EIK1001 in Advanced Melanoma

  • Eikon Therapeutics selected 0.60 mg/m² as the single dose for EIK1001 in the TeLuRide-006 study moving forward for randomized patients.
  • The independent Data Monitoring Committee (DMC) made this recommendation following a prespecified analysis of unblinded data.
  • The DMC also recommended that the TeLuRide-006 trial continue as planned in all other respects.
  • TeLuRide-006 is a Phase 2/3 registrational trial evaluating EIK1001 combined with pembrolizumab as first-line therapy for advanced cutaneous melanoma.
  • EIK1001 is an investigational dual-agonist of Toll-like receptors 7 and 8 designed to stimulate innate and adaptive immune responses.
  • Roy Baynes, M.D., Ph.D., Chief Medical Officer, stated that no statistically significant overall survival improvement has been achieved in advanced melanoma with multiple combination studies compared to checkpoint inhibitor monotherapy.
  • The company aims to advance EIK1001 as a therapy with monotherapy activity that brings a broader repertoire of immune cells to target tumor cells.